Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sheldon, Kong"'
Autor:
Rasha Khatib, Todd Williamson, Rakesh Singh, Mary Ingle, Yuxian Du, Vesta Valuckaite, Sheldon Kong, Sarang Baman
Publikováno v:
BMJ Public Health, Vol 2, Iss 1 (2024)
Background We explore how area deprivation index (ADI), a national ranking of neighbourhood sociodemographic disadvantage is associated with chronic kidney disease (CKD) screening and development among patients with newly diagnosed hypertension (HTN)
Externí odkaz:
https://doaj.org/article/ca0cd3fed228475e84855dc6f4067f97
Autor:
JULIO A. LAMPREA MONTEALEGRE, ERIN MADDEN, SRI LEKHA TUMMALAPALLI, CHI CHU, YUXIAN DU, RAKESH SINGH, SHELDON KONG, DELPHINE S. TUOT, CARMEN PERALTA, MICHAEL G. SHLIPAK, MICHELLE ESTRELLA
Publikováno v:
Diabetes. 71
Background: Recent guidelines recommend use of SGLT2i and/or GLP1-RA in persons with type 2 diabetes (T2D) and CVD or CKD, regardless of glycemic control. The degree of adoption of these recommendations thus far is unclear Methods: Among T2D patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7953a589e705f39b159d1a737facd4bf
https://doi.org/10.2337/db22-178-or
https://doi.org/10.2337/db22-178-or
Autor:
Terri Conner, Sreevalsa Appukkuttan, Sheldon Kong, Jay Jhaveri, Gilbert Ko, Bashir Kalayeh, LiHong He, Robert Sean Hauser, Arturo Loaiza-Bonilla
Publikováno v:
Journal of Clinical Oncology. 41:86-86
86 Background: Treatment options for mHSPC have continued to evolve. While androgen deprivation therapy (ADT) has been the backbone treatment, more recently early use of docetaxel and/or novel androgen receptor inhibitors (nARIs) has demonstrated imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d190f3f5e7d26813b256825486493f48
https://doi.org/10.1200/jco.2023.41.6_suppl.86
https://doi.org/10.1200/jco.2023.41.6_suppl.86
Autor:
Kevin Pantalone, Xinge Ji, Sheldon Kong, Jay Elliott, Alex Milinovich, Anita Misra-Hebert, Ryan Farej, Rakesh Singh, Janine Bauman, Robert Zimmerman, Tushar Vachharajani, Jamie Partridge, Jennifer Cameron, Todd Williamson, David Sugano, Michael Kattan
Background: Chronic kidney disease (CKD) poses substantial clinical, economic, and humanistic burden in patients with type 2 diabetes (T2D). Understanding of how to optimize patient care and slow disease progression is warranted.Objective: To compare
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3e06dfccf3d800f8b3e688291a64dcb
https://doi.org/10.21203/rs.3.rs-1101567/v1
https://doi.org/10.21203/rs.3.rs-1101567/v1
Autor:
Andrea Horvat-Broecker, Sheldon Kong, Christopher F. Bauer, Stefanie Lindemann, Christoph Wanner, Tatsiana Vaitsiakhovich, Meike Brinker, Johannes Schuchhardt, Frank Kleinjung
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Chronic kidney disease (CKD) represents a global public health problem, with significant morbidity and mortality due to cardiovascular disease during CKD progression and due to kidney failure. Although non-diabetic CKD accounts fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97601fbc8a8ecacc0ea199ae69040f94
https://doi.org/10.1093/ndt/gfab087.0046
https://doi.org/10.1093/ndt/gfab087.0046
Autor:
Johannes Schuchhardt, Tatsiana Vaitsiakhovich, Stefanie Lindemann, Christoph Wanner, Sheldon Kong, Christopher F. Bauer, Frank Kleinjung, Andrea Horvat-Broecker, Meike Brinker
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims Chronic kidney disease (CKD) is a major global health problem, affecting an estimated 850 million people worldwide. Non-diabetic CKD accounts for up to 70% of the CKD burden, which includes morbidity and mortality due to CKD progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d80e588c1fc6cf5e73d7c82a5bce9e52
https://doi.org/10.1093/ndt/gfab087.0031
https://doi.org/10.1093/ndt/gfab087.0031
Autor:
Fang Xia, Sheldon Kong, Jay Elliott, Stefanie Lindemann, Rakesh Singh, Ryan Farej, Andrew Gaiser, Xue (Snow) Feng
Publikováno v:
Diabetes. 69
Introduction: Type 2 diabetes (T2D) represents the leading cause of Chronic Kidney Disease (CKD) worldwide. While variation in T2D prevalence in the U.S. is well established, regional variation in the prevalence of CKD in patients with or without (w/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccd81125370710c0688f900d39e4f93b
https://doi.org/10.2337/db20-1479-p
https://doi.org/10.2337/db20-1479-p
Autor:
Fang Xia, Jay Elliott, Rakesh Singh, Andrew Gaiser, Xue (Snow) Feng, Bonnie B. Dean, Sheldon Kong, Stefanie Lindemann, Ryan Farej
Publikováno v:
Kidney Medicine
Rationale & Objective Regional variation in chronic kidney disease (CKD) prevalence in patients with or without type 2 diabetes mellitus (T2DM) has not been well characterized. Study Design Spatial and temporal comparative analysis. Setting & Partici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::404b5f7b51f55371de939f5de5d2704e
https://doi.org/10.1016/j.xkme.2021.09.003
https://doi.org/10.1016/j.xkme.2021.09.003
Autor:
Sheldon Kong, Jamie Partridge, Jianying Yao, Sreevalsa Appukkuttan, Stephen J. Freedland, Jacqueline Parkin, Yuxian Du
Publikováno v:
Journal of Clinical Oncology. 39:e18675-e18675
e18675 Background: Novel AA agents, such aspalutamide (Apa), enzalutamide (Enza) and darolutamide (Daro) are approved for the treatment of nmCRPC. In clinical trials, they were associated with AEs such as fatigue, fractures and falls. This study aime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d8e282e1e36381ff4abba75aa9194a11
https://doi.org/10.1200/jco.2021.39.15_suppl.e18675
https://doi.org/10.1200/jco.2021.39.15_suppl.e18675
Autor:
Stephen J. Freedland, Andrew Gaiser, Sheldon Kong, Jamie Partridge, Yuxian Du, Chunmay Fu, Sreevalsa Appukkuttan, Ashley Cha, Jacqueline Parkin
Publikováno v:
Journal of Clinical Oncology. 39:e18690-e18690
e18690 Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) are often treated with concurrent medications for the management of comorbid conditions. This increases the risk of drug interactions which may lead to compr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd13ecf32d3e9f6056311af6f01b9f55
https://doi.org/10.1200/jco.2021.39.15_suppl.e18690
https://doi.org/10.1200/jco.2021.39.15_suppl.e18690